DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key multiple myeloma patient populations covering 171 countries and more than 99% of the global population, delivered in an interactive dashboard-style download. Use the extended worldwide coverage data set to:

  • View 10-year forecasts of the first-line drug-treatable population and diagnosed incident cases for all 171 countries, stratified by region and World Bank income status.
  • Aggregate country-level estimates into region-level estimates, according to user preference or as required by regulators for orphan drug designations.
  • Visualize global correlations between disease risk or patient population size and key indicators of market opportunity such as GDP per capita and healthcare spend per capita.
  • Generate and export global heat maps of disease risk or patient population size.

The extended worldwide coverage dashboard is available as an Excel file in the “Downloads” section. It is available only to clients with subscriptions to all 45 countries covered by DRG Epidemiology. For subscription and entitlement queries, please contact questions@teamdrg.com.

Table of contents

  • Multiple Myeloma - Epidemiology - Extrapolated Worldwide Coverage
    • Extrapolated Worldwide Coverage
      • Introduction
      • Download
      • The Global Extrapolator Model
      • The Global Extrapolation Algorithm
      • Bibliography

Author(s): Ullas Ulahannan; Nishant Kumar, M.P.H.

Ullas Ulahannan, M.P.H., is an associate epidemiologist at DRG, part of Clarivate. Prior to joining DRG, he worked at Jhpiego (a John Hopkins University affiliate) as a senior program officer evaluating, implementing, and monitoring various health programs in collaboration with the state and central governments of India. He earned a B.S. in nursing from Rajiv Gandhi University and an M.P.H. from Manipal University.

Nishant Kumar, M.P.H., is an associate director on the Epidemiology team at DRG, part of Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Prior to joining DRG, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.


Related Reports

Multiple Myeloma - Landscape & Forecast - Disease Landscape & Forecast

The multiple myeloma therapy market continues to grow, fueled by the disease’s increasing incidence and long treatment durations. The availability of premium-priced branded agents prescribed...

View Details

Multiple Myeloma - Epidemiology - Emerging Markets

DRG Epidemiology’s coverage of multiple myeloma comprises epidemiological estimates of key patient populations in 45 countries w...

View Details

Multiple Myeloma - Epidemiology - Mature Markets

DRG Epidemiology's coverage of multiple myeloma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We re...

View Details

Multiple Myeloma - Epidemiology - Americas

DRG Epidemiology’s coverage of multiple myeloma comprises epidemiological estimates of key patient populations in...

View Details